GlassScriptPhysician profile
Glenn A Dubov
NPI 1407846884
$4,801.34
in general payments reported to CMS, 2019-2025
27 companies · $716 in 2025
The $716 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $479 · 2020: $495 · 2021: $571 · 2022: $734 · 2023: $929 · 2024: $877 · 2025: $716.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,456 · Education: $64.98.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,455.97 |
| Education | $64.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $982.07 | 2019-2025 | Farxiga, Lokelma |
| Fresenius USA Marketing, INC. | $491.34 | 2019-2025 | Velphoro, Velphoro, Korsuva |
| Bayer Healthcare Pharmaceuticals INC. | $441.01 | 2021-2025 | |
| Akebia Therapeutics INC | $322.44 | 2019-2025 | Vafseo, Auryxia |
| Travere Therapeutics, INC. | $244.17 | 2022-2025 | |
| Amgen INC. | $239.88 | 2019-2025 | Krystexxa, Tavneos, Parsabiv |
| Aurinia Pharma U.S., INC. | $230.00 | 2021-2025 | Lupkynis |
| Calliditas Therapeutics US INC. | $222.59 | 2022-2025 | Tarpeyo |
| Vifor Pharma, INC. | $204.41 | 2019-2023 | Veltassa |
| Horizon Therapeutics Plc | $202.19 | 2019-2023 | Krystexxa |
| Otsuka America Pharmaceutical, INC. | $177.91 | 2019-2025 | Jynarque |
| Glaxosmithkline, LLC. | $162.66 | 2021-2025 | Benlysta |
| Ardelyx, INC. | $157.96 | 2023-2025 | Ibsrela |
| Opko Pharmaceuticals, LLC | $150.87 | 2019-2022 | |
| Lilly USA, LLC | $133.56 | 2023-2025 | Jardiance |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $109.39 | 2020-2025 | Acthar |
| Daiichi Sankyo INC. | $71.07 | 2021-2022 | |
| Mallinckrodt Enterprises LLC | $46.21 | 2019 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $45.88 | 2021-2025 | Voyxact |
| Novartis Pharmaceuticals Corporation | $36.58 | 2024-2025 | |
| Amarin Pharma, INC. | $26.93 | 2019-2020 | |
| Ultragenyx Pharmaceutical INC. | $25.78 | 2019-2020 | |
| Kyowa Kirin, INC. | $18.43 | 2025 | |
| Arbor Pharmaceuticals, INC. | $16.61 | 2021 | |
| Renalytix Ai, INC. | $14.82 | 2024 | Kidneyintelx Blood Collection Convenience Kit |
| Novo Nordisk INC | $13.46 | 2025 | Wegovy |
| Alexion Pharmaceuticals, INC. | $13.12 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Glenn Dubov listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.